Diabetic nephropathy is the number one cause of endstage renal disease in the United
States. Blood pressure is most important in delaying the progression of renal disease in …

The review by Wilmer et al.(1) and the comments from Brenner (2) reflect the dilemma facing
physicians regarding the optimal approach to the blockade of the renin-angiotensin system …

Introduction. There are no adequate head-to-head comparisons of angiotensin-converting
enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) in type 2 diabetic patients …

Adequate control of blood pressure is of paramount importance in delaying the progression
of renal disease in diabetic patients. Drugs acting on renin angiotensin aldosterone axis are …

The Reduction in End Points in NIDDM with the Angiotensin II Antagonist Losartan
(RENAAL) study and the Irbesartan Diabetic Nephropathy Trial (IDNT) are two recently …

During the past decade, the incidence of end-stage renal disease (ESRD) has risen
dramatically, primarily due to an increase in the incidence of diabetes. In patients with …

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs),
two drug classes that effectively block the actions of the renin-angiotensin system (RAS) …

Many clinicians are uncomfortable about using angiotensin-converting enzyme (ACE)
inhibitors or angiotensin II type 1 receptor blockers (AT1-blockers) to treat patients with renal …

Background: Hypertension and diabetes are common risk factors for nephropathy as well as
for neuropathy, retinopathy, cardiovascular disease, and cerebrovascular disease. Diabetic …

Many traditional antihypertensive drugs are linked to various side effects that may cause
concern in the hypertensive diabetic patient. The favorable tolerability of angiotensin …